Strategies to Enhance the Therapeutic Ratio of Radiation as a Cancer Treatment

Herausgegeben:Anscher, Mitchell S.; Valerie, Kristoffer

• Gebundenes Buch

Produktbeschreibung

This volume will describe recent progress and future directions in radiation oncology and biology research, focusing on strategies designed to improve disease control and reduce the risk of long-term adverse effects on patients. As more and more patients are becoming long-term survivors, this strategy will become increasingly important--in radiation oncology and throughout the field of oncology.

Produktdetails

• Verlag: Springer / Springer International Publishing / Springer, Berlin
• Artikelnr. des Verlages: 978-3-319-45592-1
• 1st ed. 2016
• Seitenzahl: 312
• Erscheinungstermin: 3. November 2016
• Englisch
• Abmessung: 241mm x 160mm x 23mm
• Gewicht: 579g
• ISBN-13: 9783319455921
• ISBN-10: 3319455923
• Artikelnr.: 45506404

Autorenporträt

Mitchell S. Anscher, MD, FACR, FACRO, FASTRO, is Professor, Department of Radiation Oncology, Virginia Commonwealth University School of Medicine. Kristoffer Valerie, PhD, is Professor, Division of Molecular Radiobiology, Department of Radiation Oncology, Co-Leader, Radiation Biology & Oncology Program, Massey Cancer Center, Virginia Commonwealth University. 

Inhaltsangabe

1. Mechanisms of Normal Tissue Response.- 2. The Role of Hypoxia in Radiation Response.- 3. The Role of Cancer Stem Cells in Tumour Radioresponse.- 4. Novel Strategies to Prevent, Mitigate or Reverse Radiation Injury and Fibrosis.- 5. Technology Based Strategies to Enhance the Therapeutic Ratio.- 6. Nitric Oxide Synthase Uncoupling in Tumor Progression and Cancer Therapy.- 7. Aiming the Immune System to Improve the Antitumor Efficacy of Radiation Therapy.- 8. The Role of MicroRNAs in modulating Tissue Response to Radiation.- 9. Adapting Therapy Based on Tumor Response.- 10. NQO1 Bioactivatable Drugs Modify Radiation Responses.- 11. DNA Repair Pathways as a Potential Target for Radiosensitization.- 12. Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors.